Enzalutamide is primarily approved for the treatment of prostate cancer, particularly in advanced stages. It is used in metastatic castration-resistant prostate cancer (mCRPC), where the disease continues to progress despite low testosterone levels. It is also approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and, in some cases, metastatic hormone-sensitive prostate cancer (mHSPC). Its ability to target androgen receptor signaling makes it a key therapy in managing prostate cancer progression.

Enzalutamide works by directly targeting the androgen receptor, which plays a crucial role in the growth and survival of prostate cancer cells. It blocks multiple steps in the androgen receptor signaling pathway, including preventing androgens from binding to the receptor, inhibiting its movement into the cell nucleus, and stopping it from activating genes that promote tumor growth. By disrupting this pathway, enzalutamide effectively slows down or halts cancer progression.

Enzalutamide is administered orally in the form of capsules or tablets, typically taken once daily. It can be taken with or without food, but it is important to take it at the same time each day for consistent effectiveness. The dosage is determined by the treating physician and may be adjusted based on patient tolerance and response. Patients are usually advised to swallow the capsules whole and not crush or chew them. Regular follow-ups are necessary to monitor treatment response and manage any side effects.

Enzalutamide is generally well tolerated, but it can cause side effects. Common side effects include fatigue, hot flashes, weakness, dizziness, and decreased appetite. Some patients may experience hypertension, headaches, or joint pain. In rare cases, more serious side effects such as seizures, falls, or cognitive changes may occur. Because of its effects on the central nervous system, patients should be cautious when performing activities that require alertness. Regular monitoring helps in identifying and managing side effects early.

Enzalutamide should be used with caution in patients with a history of seizures or neurological disorders, as it may increase the risk of seizure activity. It is not recommended for use in women, especially during pregnancy, as it may cause harm to the fetus. Caution is also advised in patients with cardiovascular conditions, including hypertension. Drug interactions should be carefully evaluated, as enzalutamide can affect the metabolism of other medications. Close medical supervision is essential to ensure safe and effective use.

Enzalutamide represents a significant advancement in the treatment of advanced prostate cancer by targeting androgen receptor signaling more comprehensively. Its oral administration and effectiveness across different stages of the disease make it a valuable option for many patients. However, like all cancer therapies, it requires careful monitoring and individualized treatment planning. With proper medical guidance, enzalutamide can help improve outcomes and quality of life for patients living with prostate cancer.

Enzalutamide is used to treat advanced prostate cancer, including metastatic and non-metastatic castration-resistant prostate cancer, as well as certain cases of hormone-sensitive prostate cancer.

It works by blocking androgen receptor signaling, which prevents prostate cancer cells from growing and spreading.

It is taken orally once daily, with or without food, at the same time each day as prescribed by a doctor.

Common side effects include fatigue, hot flashes, dizziness, weakness, and decreased appetite. Some patients may also experience high blood pressure or joint pain, but these are usually manageable with medical guidance.

Yes, in rare cases it can cause seizures, falls, or cognitive changes. Patients should report any unusual neurological symptoms to their doctor immediately.

No, it is not chemotherapy. It is a targeted hormonal therapy that specifically blocks androgen receptor activity.

Yes, most side effects can be managed with dose adjustments, supportive care, and regular monitoring by a healthcare professional.

It is not suitable for patients with a history of seizures, certain neurological conditions, or for women who are pregnant. A doctor should evaluate each patient before starting treatment.